PMID: Am J Ther. 2015 Aug 28. Epub 2015 Aug 28. PMID: 26322676 Abstract Title: Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients. Abstract: Sorafenib is a new multikinase inhibitor; the incidence of hypertension (HTN) with sorafenib has been reported to vary substantially among clinical trials. We searched multiple databases to investigate the risk of sorafenib-induced HTN in patients with cancer. A total of 93 trials involving 20,494 patients were selected for this meta-analysis. The relative risks (RRs) of all-grade and high-grade HTN associated with sorafenib were 3.06 (P
via Health News Spirulina http://www.greenmedinfo.com/article/patients-renal-cell-carcinoma-and-thyroid-cancer-have-high-incidence-sorafenib
via Health News Spirulina http://www.greenmedinfo.com/article/patients-renal-cell-carcinoma-and-thyroid-cancer-have-high-incidence-sorafenib